Cardiovascular thromboembolic events associated with febuxostat: Investigation of cases from the FDA adverse event reporting system database
Conclusion: AERS indicated potential signals of febuxostat-associated cardiovascular thromboembolic events. AERS is not capable of establishing the causal link and detecting the true frequency of an adverse event associated with a drug. The positive IC value found in this study merits continued surveillance and assessment of cardiovascular thromboembolic events associated with Febuxostat.
Source: Seminars in Arthritis and Rheumatism - Category: Rheumatology Authors: Pranav K. Gandhi, William M. Gentry, Michael B. Bottorff Source Type: research
More News: Arthritis | Cardiology | Cardiovascular | Databases & Libraries | Gout | Heart | Heart Attack | Rheumatology | Statistics | Stroke | Study